A liquid chromatography-tandem mass spectrometry method for the simultaneous determination of exemestane and its metabolite 17-dihydroexemestane in human plasma

被引:21
作者
Corona, Giuseppe [1 ,2 ]
Elia, Caterina [2 ]
Casetta, Bruno [3 ]
Diana, Crivellari [4 ]
Rosalen, Sara [4 ]
Bari, Mario [5 ]
Toffoli, Giuseppe [2 ]
机构
[1] Natl Canc Inst, Clin & Expt Pharmacol Div, Dept Mol Biol & Translat Res, Ctr Riferimento Oncol, I-33081 Aviano, PN, Italy
[2] Ctr Mol Biomed, Aviano, PN, Italy
[3] Appl Biosyst Int, I-20052 Monza, MI, Italy
[4] Natl Canc Inst, Med Oncol Div C, I-33081 Aviano, PN, Italy
[5] PF Calvi Civ Hosp, Dept Oncol, Noale, VE, Italy
来源
JOURNAL OF MASS SPECTROMETRY | 2009年 / 44卷 / 06期
关键词
exemestane; 17-dihydroexemestane; liquid chromatography; tandem mass spectroscopy; electrospray ionization; pharmacokinetics; ADVANCED BREAST-CANCER; AROMATASE INHIBITOR; COMBINATION; PHARMACOKINETICS;
D O I
10.1002/jms.1566
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A simple and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method has been developed and validated for the quantitation of exemestane (Exe) and its main metabolite 17-dihydroexemestane (DhExe) in human plasma. The analytes were extracted by protein precipitation with acetonitrile, containing stable (13)C-labelled Exe ((13)C(3)-Exe) as internal standard, and measured by LC-MS/MS. The best chromatographic separationof the analytes from the interferences was achieved by using a Phenyl column operating under isocratic regime conditions. The total chromatographic runtime was 5.0 min and the elution of Exe and DhExe occurred at 2.5 min and 2.9 min, respectively. Quantitation was performed by employing the positive electrospray ionization (ESI) technique and multiple reaction monitoring mode (MRM). The monitored precursor to product-ion transitions for Exe, DhExe and (13)C(3)-Exe internal standard were m/z 297.0 -> 120.8, m/z 299.1 -> 134.9 and m/z 300.0 -> 123.2, respectively. The lower limit of quantitation (LLOQ) was 0.1 ng/ml for DhExe and 0.2 ng/ml for Exe. The method was linear up to 36-51 ng/ml with r(2) >= 0.998. The intra- and inter-assay precision were <= 7.7% and 5.1% for Exe and >= 8.1 and 4.9% for DhExe while deviations from nominal values were in the 1.5-13.2% and -9.0-5.8% ranges for Exe and DhExe, respectively. The analytical method resulted robust and suitable for pharmacokinetic monitoring of Exe and its main metabolite during adjuvant therapy in patients with breast cancer. Copyright (C) 2009 John Wiley & Sons, Ltd.
引用
收藏
页码:920 / 928
页数:9
相关论文
共 17 条
[1]   Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen [J].
Ariazi, Eric A. ;
Leitao, Andrei ;
Oprea, Tudor I. ;
Chen, Bin ;
Louis, Teresa ;
Bertucci, Anne Marie ;
Sharma, Catherine G. N. ;
Gill, Shaun D. ;
Kim, Helen R. ;
Shupp, Heather A. ;
Pyle, Jennifer R. ;
Madrack, Alexis ;
Donato, Anne L. ;
Cheng, Dong ;
Paige, James R. ;
Jordan, V. Craig .
MOLECULAR CANCER THERAPEUTICS, 2007, 6 (11) :2817-2827
[2]   DETERMINATION OF EXEMESTANE, A NEW AROMATASE INHIBITOR, IN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ULTRAVIOLET DETECTION [J].
BREDA, M ;
PIANEZZOLA, E ;
BENEDETTI, MS .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1993, 620 (02) :225-231
[3]   A feasibility study of the efficacy and tolerability of the combination of Exemestane with the COX-2 inhibitor Celecoxib in post-menopausal patients with advanced breast cancer [J].
Canney, P. A. ;
Machin, M. A. ;
Curto, J. .
EUROPEAN JOURNAL OF CANCER, 2006, 42 (16) :2751-2756
[4]   LC-MS-MS determination of exemestane in human plasma with heated nebulizer interface following solid-phase extraction in the 96 well plate format [J].
Cenacchi, V ;
Barattè, S ;
Cicioni, P ;
Frigerio, E ;
Long, J ;
James, C .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2000, 22 (03) :451-460
[5]   Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial [J].
Coombes, R. C. ;
Kilburn, L. S. ;
Snowdon, C. F. ;
Paridaens, R. ;
Coleman, R. E. ;
Jones, S. E. ;
Jassem, J. ;
Van de Velde, C. J. H. ;
Delozier, T. ;
Alvarez, I. ;
Del Mastro, L. ;
Ortmann, O. ;
Diedrich, K. ;
Coates, A. S. ;
Bajetta, E. ;
Holmberg, S. B. ;
Dodwell, D. ;
Mickiewicz, E. ;
Andersen, J. ;
Lonning, P. E. ;
Cocconi, G. ;
Forbes, J. ;
Castiglione, M. ;
Stuart, N. ;
Stewart, A. ;
Fallowfield, L. J. ;
Bertelli, G. ;
Hall, E. ;
Bogle, R. G. ;
Carpentieri, M. ;
Colajori, E. ;
Subar, M. ;
Ireland, E. ;
Bliss, J. M. .
LANCET, 2007, 369 (9561) :559-570
[6]   EXEMESTANE (FCE-24304), A NEW STEROIDAL AROMATASE INHIBITOR [J].
DISALLE, E ;
ORNATI, G ;
GIUDICI, D ;
LASSUS, M ;
EVANS, TRJ ;
COOMBES, RC .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1992, 43 (1-3) :137-143
[7]  
Geisler J, 1998, CLIN CANCER RES, V4, P2089
[8]   The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women [J].
Jannuzzo, MG ;
Poggesi, I ;
Spinelli, R ;
Rocchetti, M ;
Cicioni, P ;
Buchan, P .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 53 (06) :475-481
[9]   Combination therapy with aromatase inhibitors: the next era of breast cancer treatment? [J].
Leary, A. ;
Dowsett, M. .
BRITISH JOURNAL OF CANCER, 2006, 95 (06) :661-666
[10]   Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer [J].
Lonning, PE ;
Geisler, J ;
Krag, LE ;
Erikstein, B ;
Bremnes, Y ;
Hagen, AI ;
Schlichting, E ;
Lien, E ;
Ofjord, ES ;
Paolini, J ;
Polli, A ;
Massimini, G .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5126-5137